Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia.

The E2A-HLF fusion gene, generated by t(17;19)(q22;p13) in acute lymphoblastic leukemia (ALL), encodes a chimeric transcription factor in which the trans-activating domains of E2A are fused to the DNA-binding and dimerization domains of hepatic leukemic factor (HLF). To investigate its biological role, we generated transgenic mice expressing E2A-HLF using Ig enhancer and promoter, which direct transgene expression in cells committed to the lymphoid lineage. The transgenic mice exhibited abnormal development in the thymus and spleen and were susceptible to infection. The thymus contained small numbers of thymocytes, and TUNEL staining showed that higher population of thymocytes were undergoing apoptosis. The spleen exhibited a marked reduction in splenic lymphocytes and the flow cytometric analyses and the in vitro colony formation assays showed that the B-cell maturation was blocked at a very early developmental stage. These findings indicated that the expression of E2A-HLF induced T-cell apoptosis and B-cell maturation arrest in vivo and that the susceptibility of the transgenic mice to infection was due to immunodeficiency. Moreover, several transgenic mice developed acute leukemia, classified as T-ALL based on the surface marker analysis and DNA rearrangements, suggesting that an additional event is required for malignant transformation of lymphoid cells expressing E2A-HLF. Our findings provide insight into the biological function of E2A-HLF in lymphoid development and also its role in leukemogenesis.

[1]  C. Murre,et al.  Localization of E2A mRNA expression in developing and adult rat tissues. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[3]  Q. Lu,et al.  Fusion with E2A converts the Pbx1 homeodomain protein into a constitutive transcriptional activator in human leukemias carrying the t(1;19) translocation , 1994, Molecular and cellular biology.

[4]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[5]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[6]  A. Look.  E2A-HLF chimeric transcription factors in pro-B cell acute lymphoblastic leukemia. , 1997, Current topics in microbiology and immunology.

[7]  M. Cleary,et al.  Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. , 1992, Genes & development.

[8]  David Baltimore,et al.  A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B all , 1990, Cell.

[9]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[10]  Michael L. Cleary,et al.  Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor , 1990, Cell.

[11]  I. Weissman,et al.  IgH enhancer deregulated expression of L‐myc: abnormal T lymphocyte development and T cell lymphomagenesis. , 1990, The EMBO journal.

[12]  D. Pinkel,et al.  E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas , 1997, Molecular and cellular biology.

[13]  A. Look,et al.  Cell transformation mediated by homodimeric E2A-HLF transcription factors , 1997, Molecular and cellular biology.

[14]  G. Wick,et al.  Simultaneous determination of cell surface antigens and apoptosis. , 1994, Trends in genetics : TIG.

[15]  T. Inaba,et al.  E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF , 1995, Molecular and cellular biology.

[16]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[17]  D. LeBrun,et al.  Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable , 1994, Molecular and cellular biology.

[18]  H. Hsu,et al.  Enhancer-binding activity of the tal-1 oncoprotein in association with the E47/E12 helix-loop-helix proteins , 1991, Molecular and cellular biology.

[19]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[20]  David Baltimore,et al.  A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins , 1989, Cell.

[21]  S. Cory,et al.  Transgenic models of tumor development. , 1991, Science.

[22]  A. Look,et al.  Reversal of apoptosis by the leukaemia-associated E2A–HLF chimaeric transcription factor , 1996, Nature.

[23]  T. Inaba,et al.  DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein , 1994, Molecular and cellular biology.

[24]  T. Rabbitts,et al.  Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. , 1996, The EMBO journal.

[25]  H. Hsu,et al.  Formation of in vivo complexes between the TAL1 and E2A polypeptides of leukemic T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Y. Yazaki,et al.  Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. , 1998, Blood.

[27]  A. Look,et al.  The AD1 and AD2 Transactivation Domains of E2A Are Essential for the Antiapoptotic Activity of the Chimeric Oncoprotein E2A-HLF , 1998, Molecular and Cellular Biology.

[28]  S. Raimondi,et al.  Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. , 1992, Science.

[29]  C. Tribioli,et al.  Acute leukemia with promyelocytic features in PML/RARα transgenic mice , 1997 .

[30]  K. Yamamura,et al.  Strain dependency of B and T lymphoma development in immunoglobulin heavy chain enhancer (E mu)-myc transgenic mice , 1989, The Journal of experimental medicine.

[31]  Y. Yazaki,et al.  Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. , 1995, Blood.

[32]  M. Cleary.  Oncogenic conversion of transcription factors by chromosomal translocations , 1991, Cell.

[33]  L. Hu,et al.  The role of mel-18, a mammalian Polycomb group gene, during IL-7-dependent proliferation of lymphocyte precursors. , 1997, Immunity.

[34]  I. Weissman,et al.  A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .

[35]  Q. Lu,et al.  DNA-binding by oncoprotein E2a-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation. , 1996, Oncogene.

[36]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[37]  J D Kemp,et al.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow , 1991, The Journal of experimental medicine.

[38]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[39]  H. Weintraub,et al.  The helix-loop-helix gene E2A is required for B cell formation , 1994, Cell.

[40]  David P. LeBrun,et al.  Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice , 1993, Cell.

[41]  Ian Krop,et al.  E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements , 1994, Cell.